Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B].
Cai DC, Pan C, Yu WH, Dang SS, Li J, Wu SM, Jiang N, Wang MR, Zhang ZH, Lin F, Xin SJ, Yang YF, Shen BS, Ren H. Cai DC, et al. Among authors: wang mr. Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):597-600. doi: 10.3760/cma.j.issn.1007-3418.2017.08.008. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 29056009 Chinese.
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. Sun J, et al. Hepatology. 2014 Apr;59(4):1283-92. doi: 10.1002/hep.26885. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24382690 Clinical Trial.
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Hou FQ, et al. Among authors: wang mr, wang gq. Theranostics. 2015 Jan 1;5(3):218-26. doi: 10.7150/thno.10636. eCollection 2015. Theranostics. 2015. PMID: 25553110 Free PMC article. Clinical Trial.
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Fan R, et al. Gut. 2016 Feb;65(2):313-20. doi: 10.1136/gutjnl-2014-308546. Epub 2015 Jan 13. Gut. 2016. PMID: 25586058 Free PMC article. Clinical Trial.
[Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR, Zhang X, Yang ZG, Li P, Gao L, Chen XH, Wang J, Xiong X, Wang SM, Geng JB, Hao KY, Xie F, Wang M, Zheng WK. Wang MR, et al. Among authors: wang j, wang m, wang sm. Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):175-80. doi: 10.3760/cma.j.issn.1007-3418.2016.03.004. Zhonghua Gan Zang Bing Za Zhi. 2016. PMID: 27095759 Chinese.
344 results